Our Rapid Syn Bio project demonstrated the ability to build synthetic metabolic pathways for much less than the competition. The viability of synthetic pathways can now be tested much earlier in process development. We can also make sufficient product for initial characterisation studies. This will enable better process design decisions and higher throughput testing of putative IB products.
Scruffy helped take the project from TRL1 right through to TRL4-5 in a matter of months and, just as importantly, for only a few hundred quid! The project will now be taken on by a company: Tappee Biotech.